Concert Pharma begins CTP-347 phase-I trial Concert Pharmaceuticals, Inc announced that it has initiated a phase-I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert...
Antidepressants May Harm Sperm Antidepressants were linked to DNA damage in sperm Drugs taken by millions of men to alleviate depression may affect their fertility, say US scientists.A small number of healthy men given the antidepressant paroxetine for four weeks had...
Concert Pharmaceuticals initiates CTP-347 phase I clinical trial Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial - Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial LEXINGTON, Mass.- (Business Wire) announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial -Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial LEXINGTON, Mass.--(BUSINESS WIRE)-- announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial -Concert Pharmaceuticals, Inc.announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by...
TopAbstracts in Pregnancy 09/16/2008 TopAbstracts in Pregnancy are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed...
Discussion about the management of withdrawal from Seroxat (Paroxetine) and other Selective Serotonin Reuptake Discussion about the management of withdrawal from Seroxat (Paroxetine) and other Selective Serotonin Reuptake.
Superior Effectiveness and Tolerability of Escitalopram Over Paroxetine in Long-Term Treatment of Major Depres -- According to a pooled analysis of 2 randomised studies, escitalopram is more effective and safer in the long-term treatment of major depressive disorder compared with paroxetine.Siegfried Kasper, MD, Department of Psychiatry and...
Journal of the National Cancer Institute: Also in the August 12 JNCI (NewsRx.com) -- Hepatitis B Genotypes and Mutants May Influence Liver Cancer Risk Infection with hepatitis B virus (HBV) causes liver cancer in some individuals, but not all strains of the virus are associated with the same degree of risk.
Luteal phase-only paroxetine may ease premenstrual dysphoric disorder NEW YORK (Reuters Health) - In women with premenstrual dysphoric disorder (PMDD), paroxetine taken during the luteal phase significantly reduces irritability, according to results of a randomized, double-blind, placebo-controlled trial in...
Cadila Healthcare: Tough challenges ahead to reach targets Cadila Healthcare, a Rs 2350 crore plus Ahmedabad based pharma company, ranking currently at 9th among the Indian pharmaceutical companies is set to achieve a sales of over $1 billion (Rs 4350 crore) by 2010.It has set a sales target of...
